Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
CEPHULAC is an oral/rectal solution small molecule approved in 1976 for treating hepatic encephalopathy and constipation by reducing ammonia levels and promoting bowel movements. The drug works as a non-absorbable disaccharide that alters colonic pH and osmotic pressure. It remains a standard-of-care adjunct therapy for patients with liver disease and portal hypertension.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting defensive positioning and potential team reductions or reallocation to newer assets.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CEPHULAC as a Sanofi pharma professional means joining a mature brand in defensive mode, with career focus on preserving market share against generics and optimizing profitability rather than driving growth. This role suits professionals skilled in market access negotiations, cost-benefit analysis, and relationship management with hospital systems and formulary committees.
Worked on CEPHULAC at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.